What is Zacks Research’s Forecast for NTLA FY2027 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will earn ($4.87) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

A number of other research firms have also issued reports on NTLA. The Goldman Sachs Group reiterated a “sell” rating and set a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Wedbush restated a “neutral” rating and set a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Wells Fargo & Company lowered their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Citigroup lifted their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, Chardan Capital cut their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $9.31 on Monday. The firm has a 50 day moving average price of $10.07 and a 200 day moving average price of $14.05. Intellia Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $28.23. The company has a market capitalization of $963.74 million, a PE ratio of -1.71 and a beta of 1.97.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capstone Investment Advisors LLC boosted its position in Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after acquiring an additional 831 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after purchasing an additional 1,100 shares in the last quarter. Franklin Resources Inc. increased its position in Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after purchasing an additional 1,538 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock valued at $157,000 after buying an additional 1,582 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock valued at $327,000 after acquiring an additional 1,615 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Buying and Selling

In other news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. Corporate insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.